ABT-414
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
Conditions
Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
Trial Timeline
— → —
NCT ID
NCT03123952About ABT-414
ABT-414 is a pre-clinical stage product being developed by AbbVie for Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03123952. Target conditions include Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03123952 | Pre-clinical | Completed |
| NCT01741727 | Phase 1 | Completed |
Competing Products
20 competing products in Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis